Abstract

Novartis and the National Cancer Institute have developed mAbs against anthrax toxin receptor 1 that inhibited tumor angiogenesis in multiple mouse models of cancer with fewer side effects than anti-VEGF therapies. A key next step is to determine how widely the target is expressed in human tumors.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call